Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts win NICE recommendations

16th November 2017 Uncategorised 0

Pfizer’s Ibrance had a big head start on Novartis rival Kisqali in the U.S., but when it comes to England, new discount
deals with cost-effectiveness watchdogs have the contenders on more equal footing.

More: Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts win NICE recommendations
Source: fierce